CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Roche Secures FDA Clearance for VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail to Enhance B-Cell Lymphoma Diagnosis

Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Home
/
update
/
details

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

NextEdge Admin

16 Jan 2025

2 min 12 sec

Curio Bioscience,Spatial Genomics,next-generation sequencing

Takara Bio USA Holdings, a wholly owned subsidiary of Takara Bio Inc., today announced the acquisition of Curio Bioscience, a pioneering company in spatial genomics. Takara Bio, a global leader in biotechnology and life sciences headquartered in Shiga, Japan, is recognized for its innovative single-cell genomics tools. This strategic acquisition will enhance Takara Bio’s portfolio and strengthen its position in the spatial biology market.

Curio Bioscience’s advanced Trekker and Seeker technologies integrate spatial information with molecular data, enabling high-resolution insights into tissue spatial organization and molecular composition. This transformative capability allows researchers to create spatially resolved maps of cells within their native environments. “Curio Bioscience is committed to developing innovative technologies that map the entire transcriptome with unmatched sensitivity and resolution,” said Stephen Fodor, co-founder and CEO.

“The acquisition of Curio Bioscience builds on our legacy of innovation in the single-cell genomics market,” said Carol Lou, President and CEO of Takara Bio USA. “With the addition of Trekker, the first truly single-cell spatial technology, we are empowering customers with deeper insights into complex tissue systems.”

This acquisition positions Takara Bio as a leader in spatial genomics, advancing research in cancer biology, neuroscience, developmental biology, and immunology. By integrating Curio’s cutting-edge technologies with Takara Bio’s next-generation sequencing (NGS) and single-cell tools, the company continues to support groundbreaking discoveries and translational research worldwide.